当前位置: 首页 > 期刊 > 《中华现代临床医学杂志》 > 2006年第12期
编号:11119138
前列康舒胶囊治疗慢性盆腔疼痛综合征临床研究
http://www.100md.com 《中华现代临床医学杂志》 2006年第12期
慢性盆腔疼痛综合征;前列康舒胶囊;慢性前列腺炎症状评分,,慢性盆腔疼痛综合征;前列康舒胶囊;慢性前列腺炎症状评分,1资料与方法,2结果,3讨论,【参考
     【摘要】 目的 探讨前列康舒胶囊治疗慢性盆腔疼痛综合征(CPPS)的作用。方法 对196例门诊患者经EPS常规检查及细菌培养后按NIH分类标准(1995年)确诊为CPPS。口服前列康舒胶囊,每次5粒,每日3次,1个月为一疗程。分Ⅲa和Ⅲb两组进行疗效观察。2个疗程后根据治疗前后慢性前列腺炎症状评分(NIH-CPSI)和EPS中WBC计数(Ⅲa组)进行疗效评定。结果 两组治疗前后NIH-CPSI各类得分均明显改善(P<0.01),196例总显效率为46.3%,总有效率为83.1%。Ⅲb组的疗效优于Ⅲa组(P<0.05)。结论 前列康舒胶囊治疗CPPS安全、有效,尤其对非炎症性CPPS疗效更好。

    【关键词】 慢性盆腔疼痛综合征;前列康舒胶囊;慢性前列腺炎症状评分

    Clinical efficacy of Qianliekangshu capsule in the treatment of chronic pelvic pain syndrome

    LAI Yong-long,LIU Wen-Jian.Qingxi Hospital,Dongguan 523660,China

    【Abstract】 Objective To evaluate the effectiveness of Qianliekangshu capsule in the treatment of chronic pelvic pain syndrome(CPPS)patients.Methods 196 outpatients with a standard diagnosis of NIH-CPPS were classified into Ⅲa group and Ⅲb group.Two groups were treated with Qianliekangshu capsule (Orally three times daily,5pills each time) for 2 months.The efficacy was evaluated by NIH chronic prostatitis symptom index(NIH-CPSI)and leukocyte-counts in EPS(Ⅲa group)after treatment.Results After two months of treatment.There were statistically significant differences in NIH-CPSI between pre-and post-treatment(P<0.01).Obvious improvement rate and total efficiency rate was 46.3% and 83.1% respectively in 196 cases.Conclusion Qianliekangshu capsule is effective and safe for the treatment of CPPS. ......

您现在查看是摘要页,全文长 5429 字符